Life Sciences Conference

Cabbacis to Present Risk-Reduction Tobacco Products at Life Sciences Conference

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer, is set to participate in the Moody Capital Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026. Joseph Pandolfino, CEO of Cabbacicis, will deliver a corporate presentation and host one-on-one meetings with institutional investors at the conference. The company is focused on developing risk-reduction products under the iBLEND™ and X95™ brand names. Its flagship product is designed to assist in reducing nicotine exposure and dependence, transitioning to less harmful, non-combustible tobacco products, and increasing quit attempts. Cabbicis also plans to commercialize X95's very-low-nicotine tobacco cigarette without hemp and vaporizer pods containing hemp and conventional-nicotin content tobacco.